天津医药

天津医药 ›› 2017, Vol. 45 ›› Issue (3): 306-309.doi: 10.11958/20160902

• 临床研究 • 上一篇    下一篇

ERP57、 ERAP1 在乳腺癌中的表达及与临床病理特征的关系

王速捷， 古丽扎热叶·艾库拉， 韩有溪， 王义海， 木妮热·木沙江△   

  1. 新疆医科大学附属肿瘤医院乳腺放疗科 （邮编 830011）
  • 收稿日期:2016-08-24 修回日期:2017-02-13 出版日期:2017-03-15 发布日期:2017-03-21
  • 通讯作者: 木妮热·木沙江 E-mail:732250525@qq.com
  • 基金资助:
    新疆维吾尔自治区科技支疆项目计划 （指令性） 项目 （201491178）

The relationship of expressions of ERP57 and ERAP1 and clinicopathological features in patients with breast cancer

WANG Su-jie, Guzali AIKUER, HAN You-xi, WANG Yi-hai, Munira·Mushajiang△   

  1. Department of Breast Radiation, the Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, China
  • Received:2016-08-24 Revised:2017-02-13 Published:2017-03-15 Online:2017-03-21
  • Contact: Munira·Mushajiang E-mail:732250525@qq.com

PDF (PC)

3798

摘要： 摘要： 目的 观察女性乳腺癌中巯基二硫键氧化还原酶 （ERP57）、 抗原处理相关内质网氨肽酶 （ERAP1） 的表达情况， 探讨其与乳腺癌各临床病理指标的关系。方法 选取 2011 年 1 月—2015 年 12 月于新疆医科大学附属肿瘤医院收集的 124 例乳腺癌肿瘤和 24 例乳腺纤维腺瘤组织标本， 应用免疫组织化学 SP 法检测标本中 ERP57 及ERAP1 的表达情况； 根据临床病理参数对患者进行分组， 分析各组之间 ERP57、 ERAP1 的表达有无差异。结果ERP57 在乳腺癌及乳腺纤维腺瘤中阳性表达率分别为 58.8%（73/124）和 100%（24/24）， 差异有统计学意义（χ2=15.061， P＜0.05）； ERAP1 阳性表达率分别为 47.5%（59/124）和 83.3%（20/24）， 差异有统计学意义（χ2=10.328， P<0.05）。乳腺癌组织中 ERP57、 ERAP1 阳性表达率比较， 无腋窝淋巴结转移患者高于有腋窝淋巴结转移患者， 组织学分级Ⅰ级患者高于Ⅱ~Ⅲ级患者， TNM 分期Ⅰ~Ⅱ期患者高于Ⅲ~Ⅳ期患者， 差异均有统计学意义（均 P＜0.05）。此外， 乳腺癌组织中 ERAP1 阳性表达率比较， >35 岁患者高于≤35 岁患者。Ki67 阳性率≤14%患者高于>14%患者， 非三阴性患者高于三阴性患者， 差异均有统计学意义（均 P＜0.05）。结论 ERP57、 ERAP1 蛋白低表达可能与乳腺癌的发生关系密切， 这对判断乳腺癌恶性程度及预后有一定的参考价值。

关键词: 乳腺肿瘤, 巯基二硫键氧化还原酶, 抗原处理相关内质网氨肽酶

Abstract: Abstract: Objective To observe the expressions of endoplasmic reticulum chaperone (ERP57) and endoplasmic reticulum aminopep- tidase (ERAP1) in female breast cancer, and to explore their relationship with clinical pathological parameters of breast cancer. Methods A total of 124 samples of breast cancer and 24 samples of breast fibroadenoma were collected in the Affiliated Tumor Hospital of Xinjiang Medical University from January 2011 to December 2015. The expressions of ERP57 and ERAP1 were detected by immunohistochemistry SP method. The patients were divided into two groups according to the clinicopathological parameters. The differences of ERP57 and ERAP1 expression were analyzed between the groups. Results The positive expression rates of ERP57 were 58.8% (73/124) and 100% (24/24) in breast cancer and breast fibroadenoma samples, respectively. The difference was statistically significant (χ2=15.061, P＜0.05). The positive expression rates of ERAP1 were 47.5% (59/124) and 83.3% (20/24), and there was a difference between them (χ2= 10.328, P＜0.05). The positive expression rates of ERP57 and ERAP1 in breast cancer samples were higher in patients without axillary lymph node metastasis than those in patients with axillary lymph node metastasis; which were higher in patients with histological grade Ⅰ compared with those in patients with histological grade Ⅱ and Ⅲ; which were higher in patients with TNM stage Ⅰ-Ⅱ than those in patients with TNM stage Ⅲ-Ⅳ. There were significant differences between these groups (P＜0.05). In addition, the positive expression rate of ERAP1 in breast cancer was higher in patients more than 35 years old than those in patients under 35 years old. The positive rate of Ki67 was higher in patients ≤14% than that in patients >14%, and which was significantly higher in patient with non-triple negative than that in patients with the triple negative (P＜0.05). Conclusion The low expression levels of ERP57 and ERAP1 may play an important role in the carcinogenesis of breast cancer, and which may be valuable in judging the malignant degree and prognosis of breast cancer.

Key words: breast neoplasms, endoplasmic reticulum chaperone, endoplasmic reticulum aminopeptidase